Abstract 1672P
Background
Waiting involves staying in a place until an expected event occurs. From diagnosis to follow-up and treatment, cancer patients (pts) often endure waiting. Understanding their emotions during this time is crucial. Few studies have explored the experiences and emotions of cancer pts in the waiting room (WR).
Methods
An anonymous 12-item online questionnaire was distributed to cancer pts in our center's WR. The questionnaire was divided into 3 sections including clinical and socio-demographic information, time spent in the WR, and pts considerations. The aim of this study was to investigate cancer pts’ emotions and behaviors in the WR.
Results
160 pts completed the questionnaire (48% women, 52% men). The most common age groups were 51-65 years old (37%) and 66-80 years old (41%). The majority of pts are unemployed (58.5%). About half of interviewed pts undergo infusion therapies and/or visit 1-2 times monthly. When asked to describe the wait duration, approximately half found it long (32%) or too long (17%). Pts spend this period on mobile phones (47%), watching TV (21%), reading or listening to music (16%), and conversing with others (11%). Both positive (49% calm, 7.5% hopeful, 5% emotional involvement) and negative (26% boredom, 21% anxiety, 6% sadness, 5% anger, 1% apathy) emotions were experienced. The multiple logistic regression model confirms the independent predictor role for a negative emotional status in the WR of a perceived long or too long waiting period (OR=4.0, p<0.001) and the independent role of protector of male gender (OR=0.4, p0.008). A trend of significance emerged for employment (OR=0.4, p0.052) and engaging in active behaviors (OR=0.4, p0.058) as protective factors. When asked how to improve the quality of time in the WR, 38% suggested live entertainment (music, readings, and cancer information), 26% preferred access to newspapers and magazines. The most requested topics are treatment news (51%), diet (46%), and physical activity (27%).
Conclusions
For cancer pts the waiting can be a meaningful experience. Many pts find the wait long, boring, and anxiety-provoking. Our experience suggests how active and externalizing behaviors are less linked to negative emotions and interactive activities could improve the quality of time spent in the WR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1646P - A multicohort phase II trial of androgen deprivation therapy (ADT), docetaxel (DOCE) and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumours and DNA damage repair (DDR) alterations: Cohort 3 results
Presenter: Xiao Wei
Session: Poster session 11
1647P - Clinical validity of plasma DNA testing to identify BRCA-mutated (BRCA+) patients in the MAGNITUDE study
Presenter: Gerhardt Attard
Session: Poster session 11
1649P - Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial
Presenter: Dingwei Ye
Session: Poster session 11
1650P - Fuzuloparib plus abiraterone acetate and prednisone (AA-P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase I study
Presenter: Tao Dai
Session: Poster session 11
1651P - Characteristics, tolerance and effectiveness of patients aged more or less than 75 years treated with [177Lu]Lu-PSMA-617 as part of France’s early access program
Presenter: David Tonnelet
Session: Poster session 11
1652P - SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)
Presenter: Dana Rathkopf
Session: Poster session 11
1653P - Molecular and immunologic correlates of high PSMA/FOLH1 mRNA expression in prostate cancer (PC)
Presenter: Rana McKay
Session: Poster session 11
1654P - TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Poster session 11
1655P - Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study
Presenter: Lorena Incorvaia
Session: Poster session 11